8-Hydroxydeoxyquanosine as apotential tumer marker for diagnosis of prostate cancer and its association with Prostatic Specific Antigen
Keywords:
en Hydroxydeoxyquanosine,-8 pAbstract
Background
is one of the malignancies that affects men and significantly contributes to (PCa) Prostate cancer is one of the (8OHdG) Hydroxydeoxyquanosine-8 increased mortality rates in men globally. predominant forms of free radical-induced oxidative lesions, and has therefore been widely used as a mor marker Prostate Specific Antigen (PSA) is a tu tive stress and carcinogenesis. biomarker for oxida ected in the blood det ed by the prostate gland and is PSA is an enzyme produc for prostate cancer.
as tumer marker of prostate cancer 8OHdG serum Evaluation of Objective . conditions under normal and its relationship with PSA.Method This case- control study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad and at Urology department, Ghazi Al Hariri Hospital for surgical speciality during the period from March 2022 to May 2023. It included
120 men patients, 60 men patients who diagnosed to have prostate cancer ,and 60 men were apparently healthy men. Investigations included serum measurements of 8OHdG by using enzyme linked immunosorbent assay (ELISA) technique and also measurement of serum PSA. Results The results of the present study showed that there was a significant differences in 8OHdG in prostate
cancer patients as compared with the control group. The results also showed that the S.PSA were higher in the patients group compared to the controls group with significant statistical difference. Conclusion According to the results obtained we can be concluded that higher levels of 8OHdG and PSA may be associated with risk of prostate cancer.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. [PubMed]
Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011 Sep;108(6):806-13. [PubMed]
Plata Bello A, Concepcion Masip T. Prostate cancer epidemiology. Arch Esp Urol. 2014 Jun;67(5):373-82. [PubMed]
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
